Literature DB >> 34356747

Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility of Pseudomonas aeruginosa.

Emma Reece1, Pedro H de Almeida Bettio1, Julie Renwick1.   

Abstract

pan class="Species">Pseudomonas aeruginosa is one of the most dominant pathogens in span>n class="Disease">cystic fibrosis (CF) airway disease and contributes to significant inflammation, airway damage, and poorer disease outcomes. The CF airway is now known to be host to a complex community of microorganisms, and polymicrobial interactions have been shown to play an important role in shaping P. aeruginosa pathogenicity and resistance. P. aeruginosa can cause chronic infections that once established are almost impossible to eradicate with antibiotics. CF patients that develop chronic P. aeruginosa infection have poorer lung function, higher morbidity, and a reduced life expectancy. P. aeruginosa adapts to the CF airway and quickly develops resistance to several antibiotics. A perplexing phenomenon is the disparity between in vitro antimicrobial sensitivity testing and clinical response. Considering the CF airway is host to a diverse community of microorganisms or 'microbiome' and that these microorganisms are known to interact, the antimicrobial resistance and progression of P. aeruginosa infection is likely influenced by these microbial relationships. This review combines the literature to date on interactions between P. aeruginosa and other airway microorganisms and the influence of these interactions on P. aeruginosa tolerance to antimicrobials.

Entities:  

Keywords:  Pseudomonas aeruginosa; antibiotic resistance; cystic fibrosis; microbiome; polymicrobial interactions

Year:  2021        PMID: 34356747     DOI: 10.3390/antibiotics10070827

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  3 in total

1.  Mixed Populations and Co-Infection: Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  Laura Camus; Paul Briaud; François Vandenesch; Anne Doléans-Jordheim; Karen Moreau
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.

Authors:  Francesca Saluzzo; Luca Riberi; Barbara Messore; Nicola Ivan Loré; Irene Esposito; Elisabetta Bignamini; Virginia De Rose
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

3.  Synergy Between Pseudomonas aeruginosa Filtrates And Voriconazole Against Aspergillus fumigatus Biofilm Is Less for Mucoid Isolates From Persons With Cystic Fibrosis.

Authors:  Gabriele Sass; Julianne J Marsh; Pallabi Shrestha; Raquel Sabino; David A Stevens
Journal:  Front Cell Infect Microbiol       Date:  2022-04-14       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.